MOLOGEN AG
MOLOGEN is presenting two posters at International Cancer Immunotherapy Conference (news with additional features)
DGAP-News: MOLOGEN AG / Key word(s): Conference PRESS RELEASE N 14 / 2015 of 09/16/2015 MOLOGEN is presenting two posters at International Cancer Immunotherapy Conference Berlin, September 16, 2015 – The biotechnology company MOLOGEN AG is presenting two posters on the immunotherapies MGN1703 and MGN1601 at the Inaugural International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR) in New York (September 16 – 19, 2015). The first poster is outlining detailed pharmacokinetic and pharmacodynamic data from studies with the immunomodulator MGN1703 in healthy volunteers and cancer patients. The second poster is featuring immunological data from a study in renal cancer patients with the cell-based tumor vaccine MGN1601. Abstract details: Title: “Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma” For more information on the Inaugural International Cancer Immunotherapy Conference (CRI-CIMT-EATI-AACR) please visit the website http://www.aacr.org . MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200). Memberships in associations: MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=KOPJASMJLE Document title: MOLOGEN is presenting two posters at International Cancer Immunotherapy Conference 2015-09-16 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News Service |
394865 2015-09-16 |